CU
CURE.AU Global X S&P Biotech ETF
- AUD
No recent price
- Total assets
- 49.1M
- Expense ratio
- -
- Dividend yield
- -
- 1-year return
- +50.30%
- Holdings
- 10
- Since
- 2018
Fund data as reported by the issuer, updated Nov 1, 2026. Total assets are in the fund's base currency.
What does CURE.AU invest in?
Tracks MSCI World Ex Australia NR AUD- Largest sector: Healthcare (97.8%)
- Largest region: North America (93.2%)
- Top 3 holdings: 6.2% of the fund
Top holdings
- Twist Bioscience Corp 2.23%
- Moderna Inc 2.10%
- Natera Inc 1.84%
- Iovance Biotherapeutics Inc 1.65%
- Amgen Inc 1.59%
Global X S&P Biotech ETF performance
Sharpe ratio 0.85- This year
- +25.57%
- 1 year
- +50.30%
- 3 years
- +25.08%
- 5 years
- +5.44%
Volatility 28.6% over 1 year and 25.6% over 3 years. High: expect large swings.
Total returns in the fund's currency as reported by the issuer; past returns do not predict future returns. Volatility is the yearly standard deviation of returns. Ask AI to explain these numbers
CURE.AU price
Prices on the chart can differ slightly from the closing prices StockSummer shows.
Global X S&P Biotech ETF top holdings
16.9% of the fund| Holding | Sector | Country | Weight |
|---|---|---|---|
| Twist Bioscience Corp TWST.US | Healthcare | United States | 2.23% |
| Moderna Inc MRNA.US | Healthcare | United States | 2.10% |
| Natera Inc NTRA.US | Healthcare | United States | 1.84% |
| Iovance Biotherapeutics Inc IOVA.US | Healthcare | United States | 1.65% |
| Amgen Inc AMGN.US | Healthcare | United States | 1.59% |
| United Therapeutics Corporation UTHR.US | Healthcare | United States | 1.58% |
| Biogen Inc BIIB.US | Healthcare | United States | 1.55% |
| Spyre Therapeutics Inc. SYRE.US | Healthcare | United States | 1.51% |
| AbbVie Inc ABBV.US | Healthcare | United States | 1.46% |
| Halozyme Therapeutics Inc HALO.US | Healthcare | United States | 1.41% |
CURE.AU sector exposure
- Healthcare97.8%
- Financial Services0.6%
Share of the stocks in the fund.
CURE.AU regional exposure
- North America93.2%
- Europe Developed2.0%
- United Kingdom1.3%
- Asia Emerging0.0%
Share of the stocks in the fund.
Company size
Average market cap 10.5B- Big cap7.5%
- Medium cap16.1%
- Small cap45.9%
- Micro cap30.9%
Global X S&P Biotech ETF fund profile
- Fund name
- Global X S&P Biotech ETF
- Ticker
- CURE.AU
- Exchange
- Australian Securities Exchange
- Issuer
- Global X Management (AUS) Ltd
- Index tracked
- MSCI World Ex Australia NR AUD
- Category
- Global Equity
- Inception date
- Nov 8, 2018
- Trading currency
- AUD
- Expense ratio
- -